This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 163 entries.
Euroz Hartleys has published a research note on Botanix maintaining a price target of $0.80. The report addresses President Trump’s recent executive order on drug pricing and concludes it will have “little to no impact” on BOT or Sofdra™. Click here to read the full report.
Botanix CEO Howie McKibbon spoke with Stockhead’s Tylah Tully about Botanix’s elevation to the S&P/ASX 300 index, and the Company’s ambitions to become a global leader in dermatology innovation. Here’s an excerpt: “It’s a great honour and validation to join this league and a validation of the work that we’ve done and of our growth […]
Botanix CEO Howie McKibbon joined Sharecafe’s Abby Phillips this week to provide an update on the Company’s recent US launch of Sofdra™ and its commercial progress. Howie shared insights on Botanix’s experienced sales team, momentum in securing contracts with payer organizations covering over 90% of commercially insured lives plus Medicaid, and early results from a […]
Botanix Executive Director Matt Callahan spoke with Sharecafe to discuss the Company’s recent US launch of Sofdra™. Matt noted that early prescription growth is tracking to expectations only six weeks into the launch, highlighting Botanix’s unique platform that improves patient refill rates while enhancing profitability.
Botanix Pharmaceuticals is very pleased to announce that the Company will be included in the S&P/ASX 300 Index as part of the March 2025 quarterly rebalance. The S&P/ASX 300, or simply, ASX 300, is a stock market index of Australian stocks listed on the Australian Securities Exchange (ASX). The ASX 300 index covers the large-cap, mid-cap, and small-cap […]
Euroz Hartleys has published a research note on Botanix forecasting strong sales momentum for Sofdra™. Click here to read the report.
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.
The Australian Financial Review has featured Botanix as an ASX favourite. In an article profiling stock picks by Liam Donohue from Lennox Capital, he assessed the market opportunity for Sofdra™: ‘…current treatments have been more invasive (such as targeted Botox injections) and typically less effective. ‘So, with many of the more binary risks out of […]
Botanix’s significant progress towards commercialisation has been spotlighted in The West Australian’s Business section, in an article about the shipment of the Company’s ‘first batch of sweat-stopper gel’ to US patients by Cheyanne Enciso. Read article
First prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025. View release.
